In further biochemical assay, BPR1J-340 demonstrated potent inhibition (20–190 nM) against the angiogenic kinases VEGFR1, VEGFR2, and VEGFR3, which all play an important role in the tumor microenvironment (Table 1). The gene discussed is FLT4; the disease is neoplasm.